Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
M. Khalil
Institution:
University of Alabama at Birmingham
Observed institutions:
University Health Network,
Pfizer (United States),
Wayne State University,
Princess Margaret Cancer Centre,
Moffitt Cancer Center,
University of Alabama at Birmingham,
Hôpital Notre-Dame,
Abramson Cancer Center,
University of Pennsylvania
show all 9
ORCID:
0009-0007-1075-8631
Observed ORCID:
0009-0007-1075-8631
OpenAlex ID:
A5001711556
Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody
2006
·
R. H. Vonderheide
, K. T. Flaherty
, et al.
·
Journal of Clinical Oncology
·
36
1846MO Intracranial efficacy of olomorasib, a second-generation KRAS G12C inhibitor, in patients with KRAS G12C-mutant NSCLC who have active, untreated brain metastases
2025
·
P. Cassier
, J. Schneider
, et al.
·
Annals of Oncology
·
4
Tremelimumab in combination with exemestane as novel immunotherapy for patients with advanced breast cancer
2009
·
R. H. Vonderheide
, P. M. LoRusso
, et al.
·
Journal of Clinical Oncology
·
4
P1.03F.03 Utility of Patient-Derived Xenograft and Xenograft-Derived Organoid Models with EGFR Mutation to Study EGFR-TKI Resistance.
2024
·
T. Koga
, N.-A. Pham
, et al.
·
Journal of Thoracic Oncology
Show more works
View as search
Works count:
4
Citation count:
44
H-index:
3
I10-index:
1
Year
Topic
Type